Dr Duburque and colleagues from France appraised the tolerance and efficacy of an induction of tolerance protocol to infliximab.
The team assessed the efficacy of re-administration of the drug to patients with Crohn's who had infusion reactions requiring suspension of treatment.
The team evaluated 14 patients in the induction of tolerance protocol.
Each infusion of infliximab at 5 mg/kg was divided into 11 escalating 15 min increments over a 3-hour time periods.
The induction of tolerance procedure was repeated for subsequent infusions.
The researchers had 10 patients received all the 3 infusions for the induction treatment.
|7 patients achieved a complete remission, after a mean of 3 infusions|
|Alimentary Pharmacology & Therapeutics|
Of these, 9 had a significant response and 6 still benefited from infliximab infusions.
The team noted that 7 patients achieved a complete remission, after a mean of 3 infusions.
The research team observed that 4 patients had no response, and the protocol was stopped.
In addition, 3 patients experienced mild immediate hypersensitivity reactions, which were controlled.
The researchers identified 2 patients who experienced severe immediate hypersensitivity reactions.
This lead to interruption of the treatment and 1 patient developed a delayed hypersensitivity reaction.
Dr Duburque's team commented, “Our induction of tolerance protocol allows some patients who have experienced severe or repetitive infusion reactions to infliximab to be safely re-treated with the drug in a hospitalized setting, with a clinical response achieved in a majority of these patients.”